Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- A Coiled Spring: Near-Term Catalysts & Oversold Stocks
Dec 03, 2008 12:59 PM
- Transportation and Biotech: Stocks On The Rise
Sep 16, 2008 01:00 PM
- Periodicals Wrap-Up for Monday, June 2nd
Jun 02, 2008 10:18 AM
- US EQUITIES WEEK AHEAD: Home-Price, GDP Data On Agenda
May 23, 2008 12:56 PM
- Medarex: MDX-1100 Phase I Trials Had Positive Safety Data
May 21, 2008 08:33 AM
- Genentech, Celgene Seen As Winners In ASCO Data Deluge
May 16, 2008 12:33 PM
- Chasing Performance
May 16, 2008 12:00 PM
- UPDATE: Positive Lilly Cancer Drug Trial Among ASCO Releases
May 15, 2008 10:46 PM
- Positive Lilly Cancer Drug Trial Among Early ASCO Releases
May 15, 2008 09:15 PM
- MediciNova to Present At the Rodman and Renshaw 5th Annual Global Healthcare Conference and Iomai shares surge on premium buyout offer
May 14, 2008 08:59 AM
- Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Nov 24, 2008 08:01 AM
- Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
Nov 05, 2008 06:00 AM
- Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Nov 03, 2008 07:01 AM
- Medarex Announces 2008 Third Quarter Financial Results
Oct 30, 2008 04:01 PM
- Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
Oct 28, 2008 08:01 AM
- PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Sep 24, 2008 09:02 AM
- Medarex to Present at the UBS Global Life Sciences Conference
Sep 17, 2008 04:00 PM
- Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year
Sep 15, 2008 10:17 AM
- Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Sep 08, 2008 08:04 AM
- Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
Sep 04, 2008 08:02 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
MEDX
|
Compare to S&P
|
| YTD |
-57.01 %
|
-0.01 %
|
| 4 Weeks |
-39.78 %
|
-28.65 %
|
| 12 Weeks |
-33.03 %
|
-3.39 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 15.38 %
|
|
EPS Growth in Last Year: 8.33 %
|
|
Sales Growth in Last Quarter: 2.49 %
|
|
Sales Growth in Last Quarter: -17.86 %
|
|
|
